ESR1 and gastric cancer: Extensive research has confirmed that chelerythrine (2) is capable of affecting estrogen signaling pathways (e.g., the estrogen receptor ER- α 36, ER- α 66, ER-β1, and Src expression), inhibiting gastric cancer cell (AGS) growth proliferation, and facilitating their apoptosis [32].